Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preladenant +/- Pembrolizumab in Advanced Solid Tumors
NCT03099161Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of preladenant in solid tumor (3 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting Toxicities, Adverse Events up to 8 months and 1 more. Started Jun 2017; status: terminated.
02
Drugs
preladenant
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03099161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099161.